methyl 6-ureidohexanoate | 1029287-72-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: methyl 6-ureidohexanoate
• 英文别名: methyl 6-(carbamoylamino)hexanoate
• CAS: 1029287-72-6
• 化学式: C₈H₁₆N₂O₃
• mdl: MFCD12144297
• 分子量: 188.227
• InChiKey: IYWGYAPJMLEBFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  13
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  81.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 6-ureidohexanoate 、 乙酰丙酮苄酯 、 苯甲醛 在 盐酸 作用下， 以 四氢呋喃 为溶剂， 生成 Benzyl 3-(6-methoxy-6-oxohexyl)-4-methyl-2-oxo-6-phenyl-1,6-dihydropyrimidine-5-carboxylate
  参考文献：
  名称：

  Pyrimidinone-peptoid hybrid molecules with distinct effects on molecular chaperone function and cell proliferation

  摘要：

  The Hsp70 molecular chaperones are ATPases that play critical roles in the pathogenesis of many human diseases, including breast cancer. Hsp70 ATP hydrolysis is relatively weak but is stimulated by J domain-containing proteins. We identified pyrimidinone-peptoid hybrid molecules that inhibit cell proliferation with greater potency than previously described Hsp70 modulators. In many cases, anti-proliferative activity correlated with inhibition of J domain stimulation of Hsp70. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.12.014
• 作为产物：
  描述：

  6-[(氨基羰基)氨基]己酸 、 三甲基硅烷化重氮甲烷 以 甲醇 、 正己烷 、 苯 为溶剂， 反应 1.0h， 生成 methyl 6-ureidohexanoate
  参考文献：
  名称：

  Pyrimidinone-peptoid hybrid molecules with distinct effects on molecular chaperone function and cell proliferation

  摘要：

  The Hsp70 molecular chaperones are ATPases that play critical roles in the pathogenesis of many human diseases, including breast cancer. Hsp70 ATP hydrolysis is relatively weak but is stimulated by J domain-containing proteins. We identified pyrimidinone-peptoid hybrid molecules that inhibit cell proliferation with greater potency than previously described Hsp70 modulators. In many cases, anti-proliferative activity correlated with inhibition of J domain stimulation of Hsp70. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.12.014

文献信息

• Methods for heat shock protein dependent cancer treatment
  申请人：Batuman Olcay

  公开号：US08754094B2

  公开（公告）日：2014-06-17

  The present invention provides a method of treating an Hsp70 dependent cancer, including: providing at least one Hsp70 dependent cancer cell; contacting the at least one cell with a sub-effective concentration of a dihydropyrimidinone compound; and contacting the at least one cell with a sub-effective concentration of a proteasome inhibitor, wherein the sub-effective concentration of the dihydropyrimidinone compound and the sub-effective concentration of the proteasome inhibitor have a synergistic effect upon the at least one cell.

  本发明提供了一种治疗Hsp70依赖性癌症的方法，包括：提供至少一种Hsp70依赖性癌细胞；将至少一种细胞与亚有效浓度的二氢嘧啶酮化合物接触；并将至少一种细胞与亚有效浓度的蛋白酶体抑制剂接触，其中二氢嘧啶酮化合物的亚有效浓度和蛋白酶体抑制剂的亚有效浓度对至少一种细胞具有协同作用。
• METHODS FOR HEAT SHOCK PROTEIN DEPENDENT CANCER TREATMENT
  申请人：Batuman Olcay

  公开号：US20110160160A1

  公开（公告）日：2011-06-30

  The present invention provides a method of treating an Hsp70 dependent cancer, including: providing at least one Hsp70 dependent cancer cell; contacting the at least one cell with a sub-effective concentration of a dihydropyrimidinone compound; and contacting the at least one cell with a sub-effective concentration of a proteasome inhibitor, wherein the sub-effective concentration of the dihydropyrimidinone compound and the sub-effective concentration of the proteasome inhibitor have a synergistic effect upon the at least one cell.
• US8754094B2
  申请人：——

  公开号：US8754094B2

  公开（公告）日：2014-06-17
• [EN] METHODS FOR HEAT SHOCK PROTEIN DEPENDENT CANCER TREATMENT<br/>[FR] PROCÉDÉS DE TRAITEMENT DU CANCER DÉPENDANT D'UNE PROTÉINE DE CHOC THERMIQUE
  申请人：UNIV NEW YORK STATE RES FOUND

  公开号：WO2009023846A2

  公开（公告）日：2009-02-19

  The present invention provides a method of treating an Hsp70 dependent cancer, including: providing at least one Hsp70 dependent cancer cell; contacting the at least one cell with a sub-effective concentration of a dihydropyrimidinone compound; and contacting the at least one cell with a sub-effective concentration of a proteasome inhibitor, wherein the sub-effective concentration of the dihydropyrimidinone compound and the sub-effective concentration of the proteasome inhibitor have a synergistic effect upon the at least one cell.